Clinical Trial Update: LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update for LDK378 in crizotinib-naïve adults with ALK-activated non-small cell lung cancer completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• LDK378 (Alectinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2019-02-12